EMCDDA news

Speech by Alexis Goosdeel: European Drug Report 2020: Trends and Developments — Key findings

Occasion: Virtual event, European Drug Report 2020: Trends and Developments — Key findings Introduction Good morning, It is my pleasure to present to you the new report on the drug situation in Europe and it is a privilege to present it to you with Mrs Ylva Johansson, European Commissioner for Home Affairs and with Mrs Laura d’Arrigo, Chair of the Management Board of the EMCDDA. 30.09.2020 
Čtěte více

Looking back on 25 years of annual reporting on the drugs problem in Europe

This month, the EMCDDA's Scientific Director takes us on a journey through 25 years of annual reporting on the drugs problem in Europe. The journey begins with the first report describing the drug situation in 1995 and leads us, over key milestones, to the latest European Drug Report 2020. Looking back on a quarter of a century, two things stand out: first, Europe's drugs problem has evolved considerably over this period; and second, this evolution has been accompanied by a dramatic increase in the quantity and quality of the information available on the topic. 30.09.2020 
Čtěte více

EMCDDA and Kosovo seal new agreement in Pristina

The EMCDDA and Kosovo* are signing a new Working Arrangement today which will pave the way for greater cooperation on monitoring the drug phenomenon in Europe and beyond its borders. Dignitaries attending the ceremony in Pristina are: Kosovo’s Minister of Internal Affairs, Agim Veliu; Minister of Health, Armend Zemaj; and the new EU Ambassador in Kosovo, Tomaš Szunyog. EMCDDA Director Alexis Goosdeel will participate in the ceremony virtually. 28.09.2020 
Čtěte více

COVID-19 disruption and a strong drug market bring new threats to health and security in Europe

High availability across all drug types, drug production within Europe and highly potent substances are among the concerns addressed today by the EU drugs agency (EMCDDA) in its European Drug Report 2020: Trends and Developments (1). In its latest annual review — marking 25 years of monitoring — the agency describes the drug situation at the end of 2019, along with recent changes brought by the COVID-19 pandemic in early 2020.
Čtěte více

TOPlist